DARWIN II (NCT02314481) is an exploratory phase II study examining the role of intratumor heterogeneity and presence of neoantigens on the effectiveness of anti-PD-L1 immunotherapy in EGFR or HER2 mutated NSCLC patients with relapsed disease after afatinib therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.